Overcoming Fear of ‘CPV Monster,’ Drug Makers Launch Continued Process Verification Programs
This article was originally published in The Gold Sheet
Executive Summary
Most pharmaceutical manufacturers are adopting or making plans to adopt the continued process verification approach outlined in FDA’s November 2011 process validation guidance, which will shine a light on their manufacturing processes. But not everyone is anxious to see what that light will reveal.
You may also be interested in...
CPV Shines New Light on Old Manufacturing Processes
Biopharmaceutical manufacturers say that implementation of continued process verification has helped to update “archaic” manufacturing processes for legacy products and uncover problems with raw materials. They have reaped some business benefits as well.
FDA’s Quality Metrics Proposal Poses Challenges, Including Gaming, Cost
If it works, the quality metrics initiative outlined in draft FDA guidance will help the global pharmaceutical supply chain prevent quality failures and drug shortages. But there will be challenges.
FDA’s Quality Metrics Proposal Poses Challenges, Including 'Gaming,' Cost
If it works, tracking the four quality metrics outlined in FDA guidance will help the global pharmaceutical supply chain prevent quality failures and drug shortages.